Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Return on Equity: 2016-2025

Historic Return on Equity for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to -12.11%.

  • Editas Medicine's Return on Equity fell 1108.00% to -12.11% in Q3 2025 from the same period last year, while for Sep 2025 it was -12.11%, marking a year-over-year decrease of 1108.00%. This contributed to the annual value of -0.98% for FY2024, which is 55.00% down from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Return on Equity is -12.11%, which was down 110.57% from -5.75% recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Return on Equity registered a high of -0.27% during Q2 2021, and its lowest value of -12.11% during Q3 2025.
  • Over the past 3 years, Editas Medicine's median Return on Equity value was -0.73% (recorded in 2024), while the average stood at -2.40%.
  • In the last 5 years, Editas Medicine's Return on Equity surged by 32bps in 2021 and then tumbled by 1,108bps in 2025.
  • Over the past 5 years, Editas Medicine's Return on Equity (Quarterly) stood at -0.34% in 2021, then dropped by 23bps to -0.57% in 2022, then climbed by 14bps to -0.43% in 2023, then tumbled by 110bps to -1.53% in 2024, then crashed by 1,108bps to -12.11% in 2025.
  • Its Return on Equity was -12.11% in Q3 2025, compared to -5.75% in Q2 2025 and -2.55% in Q1 2025.